Request the Llusern investor pack

Llusern Scientific is developing treatment-directing diagnostics that support faster, better-informed treatment decisions. Its first focus is

Lodestar DX, a portable molecular UTI testing system designed for near-patient use by professional users. For further information on the company, product, commercial model and progress to date, request the Llusern investor pack.

A focused diagnostics company with a clear first product

Llusern is starting with rapid UTI testing, a common diagnostic need where faster information can support better-informed treatment decisions.

Lodestar DX brings molecular UTI testing closer to the patient, with a portable system designed for professional use in human and veterinary settings.

Investor Pack

A focused diagnostics company with a clear first product

Llusern is starting with rapid UTI testing, a common diagnostic need where faster information can support better-informed treatment decisions.

Lodestar DX brings molecular UTI testing closer to the patient, with a portable system designed for professional use in human and veterinary settings.

The content here is the exact same as in the dark section above
Speak to the Team

Key information at a glance

Clear first product

Flagship
Lodestar DX is Llusern's flagship product and first commercial focus.

Near-patient molecular testing

Efficiency
Designed to bring rapid molecular UTI testing closer to the point of decision.

Less than 40 minutes

Performance
Sample-to-result in less than 40 minutes.

Professional-use settings

Versatile
Designed for professional users in human and veterinary settings.

Device-plus-consumables opportunity

Versatile
A portable analyser with recurring UTI test panel potential.

Broader platform potential

Versatile
Starting with UTI, with wider potential for treatment-directing diagnostics over time.

A practical product for a recurring diagnostic need

Lodestar DX is designed around speed, portability and simplicity. It detects six key UTI-causing bacterial pathogens from a small urine sample, requires only 10 μL of urine and does not require an extraction step.

This gives Llusern a focused product opportunity in rapid UTI testing, with relevance across professional healthcare and veterinary settings.

About Lodestar SX

Built by a credible multidisciplinary team

Llusern brings together expertise across microbiology, molecular genetics, product development, regulatory compliance, urology, infectious disease and commercial diagnostics. The team combines scientific depth with practical product development and commercial focus.

Dr Emma Hayhurst

Executive Chair

Martyn Lewis

Chief Executive Officer

Dr Jeroen Nieuwland

Chief Scientific Officer

Mark Preston

Chief Technology Officer

Request investor pack

To receive the Llusern investor pack, please complete the form below. Some information may be shared following review and, where appropriate, under confidentiality arrangements.

Fill the form below

Investor Information